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Abstract
Tapinarof, a novel, first-in-class small-molecule topical therapeutic aryl hydrocarbon receptor
(AhR) modulating agent (TAMA), is in clinical development for the treatment of psoriasis and
atopic dermatitis. The efficacy of tapinarof in psoriasis is attributed to its specific binding and
activation of AhR, a ligand-dependent transcription factor, leading to the downregulation of
pro-inflammatory cytokines, including interleukin-17, and regulation of skin barrier protein
expression to promote skin barrier normalization. AhR signaling regulates gene expression
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in immune cells and skin cells, and has critical roles in the regulation of skin homeostasis.
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Tapinarof-mediated AhR signaling underlies the mechanistic basis for the significant efficacy
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and acceptable tolerability observed in early phase clinical trials of tapinarof cream in the
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treatment of psoriasis.
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INTRODUCTION
Plaque psoriasis is a common, chronic, immune-mediated disease characterized by scaly,
erythematous and pruritic well-demarcated lesions that can be painful and disfiguring.1, 2 The
burden of psoriasis is reported to be similar to that of other chronic conditions, such as
congestive cardiac failure and chronic lung disease, and includes significant physical,
psychological, and socioeconomic burdens.3-6 People with psoriasis are at increased risk of
anxiety and depression,7-9 and experience an increased incidence of several comorbidities.3,

of
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While the introduction of biologics and systemic agents targeting key immune pathways,
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such as the interleukin (IL)-23/IL-17 axis, has significantly advanced treatment particularly of

re

more severe disease, conventional topical treatments are used by the vast majority of

lP

patients with psoriasis.1, 13, 14 Topical agents forming the mainstay of psoriasis treatment
include corticosteroids, vitamin D derivatives (calcipotriene, calcitriol), vitamin A derivatives

na

(tazarotene), anthralin, and coal tar,15 with topical corticosteroids and vitamin D derivatives

ur

being the most frequently prescribed.16 While efficacious, topical corticosteroids have
restrictions regarding duration, location, and extent of use. The effectiveness of

Jo

corticosteroids may also be limited by the potential for tachyphylaxis, and recurrence of
symptoms associated with reduced frequency or cessation of treatment.16 Other topical
agents, such as calcipotriene and tazarotene, have well-documented adverse events, such
as skin irritation.15, 17 Considering the importance of topical agents in psoriasis, few options
with novel mechanisms have been introduced in recent years, and the need for more
effective and well-tolerated topical therapies remains (Table I).
Tapinarof is a novel, first-in-class, small molecule topical therapeutic aryl hydrocarbon
receptor (AhR) modulating agent (TAMA) currently in late-stage clinical trials for the
treatment of psoriasis and atopic dermatitis. Here, the unique mechanism of action of
tapinarof cream for the treatment of psoriasis is reviewed in the context of the current
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understanding of AhR signaling in the skin and a growing body of clinical trials evidence on
the efficacy and safety of tapinarof cream in psoriasis18, 19 and atopic dermatitis.20-22

THE ARYL HYDROCARBON RECEPTOR
AhR is a ligand-dependent transcription factor
AhR is a ligand-dependent transcription factor that regulates gene expression in a range of
cells, including immune and epithelial cells. In healthy skin, AhR signaling plays an integral
part in maintaining skin homeostasis by regulating the skin immune network, keratinocyte

ro

of

differentiation, skin barrier function and pigmentation, and responses to oxidative stress.23, 24
AhR is crucial to maintaining homeostasis by mediating responses to xenobiotic and

-p

environmental challenges and is activated by a wide range of low molecular weight ligands
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found in endogenous, dietary, environmental, and microbial sources.23, 25, 26 Endogenous

lP

AhR ligands include indigoids, heme metabolites, and arachidonic acid metabolites. Dietary

na

AhR ligands include flavonoids, carotenoids, and metabolites of commensal gut bacteria,26

biphenyls.27

ur

while environmental ligands include polycyclic aromatic hydrocarbons and polychlorinated-
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An important characteristic of AhR is its differential activation by this wide range of ligands.
Upon ligand binding in the cytoplasm, the activated AhR-ligand complex heterodimerizes
with the AhR nuclear translocator (ARNT), resulting in transformation of the complex into a
high-affinity DNA-binding transcription factor. The AhR-ligand/ARNT complex binds to
specific DNA recognition sites, resulting in transcriptional control of AhR-responsive
genes.28, 29 In addition to its direct effect on gene transcription, AhR can signal through other
transcription factors, such as nuclear factor kappa-B and nuclear factor erythroid 2-related
factor 2 (Nrf2), to modulate gene expression.28-30 Thus, depending on the specific ligand,
binding to AhR can result in induction or repression of different genes, causing diverse
biologic responses in numerous tissue types.31

5

How different ligands activate AhR to cause such diverse responses has been an area of
research for numerous years. While the diverse molecular mechanisms of AhR binding and
downstream signaling remain to be fully elucidated, its therapeutic potential in skin disease
has become a focus of attention given growing evidence for the essential role of AhR
signaling in regulating inflammatory responses and skin homeostasis.31-33
AhR signaling and psoriasis
AhR is widely expressed in immune cells, including antigen-presenting cells, T cells,
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fibroblasts, macrophages, mast cells, and other skin immune cells, with the expression of
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AhR being necessary for the functioning of antigen-presenting cells, including Langerhans
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cells, and cytokine expression.23 AhR signaling has been shown to regulate the terminal
differentiation of CD4+ T helper (Th)17 and Th22 cells, as well as the expression of IL-17
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and IL-22 cytokines.32, 34

AhR is expressed in keratinocytes, and AhR signaling regulates keratinocyte terminal

na

differentiation, promotes skin barrier integrity, and prevents trans-epidermal water loss.35, 36
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To maintain skin barrier integrity, AhR activation and signaling has been shown to
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upregulate barrier protein gene expression, including filaggrin.28 Additionally, AhR-mediated
activation of transcription factors such as Nrf2 induce cytoprotective antioxidant responses
that suppress oxidative stress and restore skin homeostasis.24, 28
The contribution of aberrant immune responses to the pathogenesis of psoriasis is well
established and supported by the demonstrated efficacy and approval of biologics that
selectively target cytokines, such as tumor necrosis factor α, IL-23, and IL-17A.14 The
immune response in psoriasis is characterized by increased skin infiltration and activation of
effector CD4+ T cells, including the upregulation of Th17 and Th22 cells.37, 38 Crosstalk
between immune cells and skin cells contributes to the formation and exacerbation of
psoriatic plaques and, histologically, psoriasis is characterized by aberrant differentiation and
hyperproliferation of keratinocytes in the upper layers of the epidermis.2 Further, in psoriasis,
abnormal epidermal differentiation and impaired skin barrier function has been associated
6

with downregulation of skin barrier protein expression, including filaggrin and loricrin.39
Oxidative stress has also been implicated in the pathogenesis of psoriasis, through a
pathogenic effect that results in cellular damage, inflammation, and impairment of skin
barrier function.40-42
Current understanding of the expression and function of AhR in the skin supports further
investigation into AhR signaling as a therapeutic target in psoriasis and other inflammatory
skin diseases. Non-specific modulation of AhR signaling possibly underlies the mechanism
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of action of coal tar, one of the oldest topical treatments in psoriasis, which contains a
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mixture of organic compounds including polycyclic aryl hydrocarbons that may activate AhR
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to exert a therapeutic effect.43, 44
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A potential functional role of AhR in psoriasis has been demonstrated in AhR-deficient mice

lP

that developed exacerbated psoriasiform skin inflammation with increased IL-17 and IL-22
expression in an imiquimod-induced psoriasis model. Additionally, treatment of wild-type
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mice with 6-formylindolo[3,2-b]carbazole, an endogenous AhR ligand found in skin,
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model.45

ur

ameliorated psoriasiform skin inflammation and pathology in an imiquimod-induced psoriasis

In patients with psoriasis, dysregulated AhR expression has been demonstrated. Increased
serum levels of AhR were identified in patients with psoriasis compared with healthy
subjects.46 Increased AhR expression in peripheral blood mononuclear cells of patients with
psoriasis was associated with increased Th22 cells and IL-22 expression compared with
healthy subjects.47 Increased AhR expression has been identified in skin biopsies of patients
with psoriasis,48 and treatment of skin cells with AhR ligands in vitro resulted in the
modulation of genes implicated in the pathogenesis of psoriasis, including IL-6, IL-8, and
type I and II interferon pathway genes.45, 48
Taken together, these findings suggest that AhR ligation may modulate downstream effector
functions of AhR signaling to impact multiple mechanisms contributing to the development of
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psoriasis. The specific binding and activation of AhR by tapinarof leads to the modulation of
a unique set of target genes that are dysregulated in psoriasis and includes IL-17, thus
exerting therapeutic effects that are distinct from other AhR ligands.49 This is significant
because the activity of AhR is highly ligand-dependent, and several naturally occurring and
synthetic AhR ligands are known to exert differential biologic effects via the AhR
transcription factor and downstream pathways.23

TAPINAROF AS A TREATMENT FOR PSORIASIS

of

Tapinarof discovery

ro

The discovery of tapinarof (DMVT-505; previously known as WBI-1001 and GSK2894512)

-p

was a fortuitous outcome of investigations into the secondary metabolites of Photorhabdus
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luminescens, a bioluminescent, gram-negative bacillus, which lives symbiotically within

lP

parasitic, soil-living entomopathogenic nematodes of the genus Heterorhabditis.50, 51 P.
luminescens is essential to the reproduction of the nematode, as the worm carries the

na

symbiont in its intestines and, upon entering a host insect, releases the bacilli, which help to

ur

preserve insect tissue in optimal conditions for nematode growth.51, 52
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In 1959, Dutky first noted that insects infected by the nematode did not putrefy once dead, in
contrast to the rapid decay seen in the absence of the nematode.53 It was therefore
postulated that P. luminescens was producing metabolites with antimicrobial and other
properties responsible for the observed biologic effect. One such metabolite was purified and
identified as 3,5-dihydroxy-4-isopropylstilbene, a small molecule with a low molecular weight
(254 g/mol).51, 54 Pharmaceutical development of 3,5-dihydroxy-4-isopropylstilbene
(tapinarof) identified the compound to have anti-inflammatory properties.55 The mechanism
of action of tapinarof was elucidated by profiling against more than 800 potential cellular
targets, including a diverse array of kinases and other intracellular enzymes, nuclear
receptors, transcription factors, and mediators of epigenetic signaling, where the most potent
interactions were observed with AhR.33 Tapinarof was found to bind directly to AhR, resulting
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in downregulation of inflammatory cytokines, regulation of skin barrier protein expression,
and antioxidant activity.33, 49
Tapinarof-modulated AhR signaling in immunomodulation
One of the proposed mechanisms for the observed clinical effect of tapinarof in patients with
psoriasis is via the suppression of key Th17/Th22 cytokines, IL-17, and IL-22. In a T-cell
polarization assay, tapinarof markedly inhibited T-cell expansion and Th17-cell
differentiation, and reduced the production of IL-17,33 while also reducing IL-17A and IL-17F

of

levels in a CD4+ T-cell assay.33 In a mouse model of psoriasis, tapinarof treatment

ro

downregulated inflammatory cytokine expression in skin tissue, including IL17A, IL17F, IL19,
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IL22, IL23A, and IL1β gene expression.33 The downregulation of cytokines by tapinarof was
not observed in AhR-deficient mice, supporting the conclusion that tapinarof has an anti-
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inflammatory role mediated via AhR signaling in vivo.33

Tapinarof-modulated AhR signaling in regulating keratinocyte function

na

The regulation of skin barrier protein expression and normalization of skin cell differentiation

ur

via modulation of the AhR signaling pathway both provide a mechanistic rationale for the

21

Jo

therapeutic effects of tapinarof observed in clinical trials of psoriasis and atopic dermatitis.18,
Tapinarof has been shown to induce expression of skin barrier genes related to

keratinocyte differentiation33 that are downregulated in psoriasis, including filaggrin and
loricrin.56 The role of tapinarof in restoring epidermal function to promote normalization of
skin barrier mechanisms is also supported by the finding that AhR-deficient keratinocytes are
hyper-responsive to pro-inflammatory cytokines, exhibit increased production of
inflammatory mediators, and develop psoriatic pathology.57, 58
Tapinarof-modulated AhR signaling in reduction of oxidative stress
In patients with psoriasis, increased circulating reactive oxygen species (ROS) and
decreased antioxidant levels are associated with increased disease severity.59 Tapinarof is a
stilbene molecule containing two phenol groups that directly scavenge ROS, including
superoxide anions and hydroxyl radicals, demonstrating intrinsic antioxidant activity.33
9

Tapinarof also induces the AhR-Nrf2 transcription factor pathway leading to expression of
antioxidant enzyme genes, such as NAD(P)H, quinone oxidoreductase 1, and heme
oxygenase‐1, to reduce ROS.24, 33 AhR-mediated antioxidant activity and subsequent ROS
reduction has been demonstrated to reduce inflammatory responses, including decreasing
keratinocyte IL-8 expression.60 Thus, the combined antioxidant response through the Nrf2
pathway and direct ROS scavenging by tapinarof may together reduce epidermal oxidative
stress known to cause significant cellular damage to skin in the pathogenesis of psoriasis.

of

Tapinarof in psoriasis clinical trials

ro

Initial clinical proof-of-concept studies were conducted using a different formulation of
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tapinarof cream, WBI-1001. A phase 2 study demonstrated that WBI-1001 1% concentration

re

cream applied twice daily (BID) for 12 weeks significantly improved Physician Global

lP

Assessment (PGA) scores compared with vehicle in patients with mild to moderate plaque
psoriasis. Adverse drug reactions, mostly at application sites, were more frequent with active

na

treatment than with vehicle, but all were mild or moderate in intensity.55 WBI-1001 was later

ur

reformulated to enhance the drug product’s stability and delivery, resulting in the current

Jo

formulation of tapinarof cream in clinical development, which was evaluated in a phase 2b
dose-ranging study in patients with mild to severe plaque psoriasis. In this study, patients
were randomized to tapinarof cream 0.5% or 1% once daily (QD) or BID, or vehicle QD or
BID for 12 weeks with a 4-week treatment-free follow-up. The primary endpoint was PGA
score 0 or 1 and ≥2-grade improvement at week 12. The proportion of patients achieving the
primary endpoint was significantly higher in all tapinarof cream groups than in vehicle groups
(65% [1%BID], 56% [1%QD], 46% [0.5%BID], and 36% [0.5%QD] versus 11% [vehicle BID]
and 5% [vehicle QD]), and was maintained for 4 weeks after the end of treatment through
Week 16 in all tapinarof groups except for the 0.5%BID group. Clinically meaningful
improvements in psoriasis outcomes were observed as early as 2 weeks of treatment with
tapinarof cream, and significant improvements were maintained for 4 weeks after treatment
discontinuation. Tapinarof was generally well tolerated and most treatment-emergent
10

adverse events were mild or moderate in severity.18 The safety and efficacy of tapinarof 1%
cream QD is being evaluated in a pivotal phase 3 psoriasis clinical program, which
comprises two randomized controlled trials in adults with plaque psoriasis, with expected
completion in 2020 (NCT02564042 and NCT03983980).
Evidence thus far demonstrates that tapinarof-mediated AhR activation has the potential to
exert multiple mechanistic effects in psoriasis from immune modulation to the regulation of
skin barrier function, which is supported by the potential of AhR to control gene transcription

of

directly or indirectly through other transcription factors, and its wide expression in different

ro

cell types and tissues (Fig 1). In psoriasis, the totality of in vitro, ex vivo, and in vivo data

-p

support an anti-inflammatory mechanism in which tapinarof/AhR/ARNT complexes directly

re

bind to the IL17A promotor and suppress IL17A transcription. Additionally, the observation
that methylation of the IL17A promoter is increased in response to tapinarof provides further

lP

support for an anti-inflammatory effect mediated by decreased expression of IL-17A upon

na

treatment (Dermavant Sciences, Inc. Unpublished data); the latter epigenetic modification of
the IL17A promoter may explain, in part, the durability of therapeutic effect in the phase 2b

ur

clinical trial where significant improvements were maintained for 4 weeks after

Jo

discontinuation of tapinarof in patients with psoriasis.18
Further studies will contribute to a more precise mechanistic understanding of how AhR
activation by tapinarof leads to downstream effector functions and is an opportunity for future
study with tapinarof cream to further support the translation of its mechanistic effects to
clinical outcomes in patients with psoriasis.

CONCLUSIONS
The efficacy of tapinarof in psoriasis is attributed to its activation of AhR, a ligand-dependent
transcription factor, which modulates gene expression of IL-17 and skin barrier proteins to
exert an anti-inflammatory effect and promote skin barrier normalization, respectively, in
addition to its antioxidant activity.33, 49 Tapinarof binds to a specific site on AhR, leading to
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unique biologic outcomes that manifest clinically as significant therapeutic efficacy for a
topical agent in the treatment of inflammatory skin diseases.61 Tapinarof has been effective
and generally well tolerated in clinical trials to date, and the positive phase 2 findings have
led to progression to a pivotal phase 3 clinical trial program. Further data from those clinical
trials will provide a greater understanding of the benefits and safety and tolerability profile of
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tapinarof in the management of psoriasis.
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Fig 1. Potential mechanisms of action of tapinarof in the treatment of psoriasis.
Tapinarof activation of the aryl hydrocarbon receptor modulates gene expression that leads
to significant reduction of Th17 cytokines implicated in plaque psoriasis, including IL-17A
and IL-17F*†‡; increase in antioxidant response through the Nrf2 pathway, as well as direct
ROS scavenging by tapinarof*†; and regulation of skin barrier protein expression, including
filaggrin and loricrin.*
*Demonstrated in vitro. †Demonstrated ex vivo; ‡Demonstrated in mouse models.
AhR, Aryl hydrocarbon receptor; ARNT, aryl hydrocarbon receptor nuclear translocator;
FLG, filaggrin; IL, interleukin; LOR, loricrin; Nrf2, nuclear factor erythroid 2-related factor 2;
ROS, reactive oxygen species; TAP, tapinarof.
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Table I: Tapinarof* and FDA-approved topical monotherapy for the treatment of plaque psoriasis

-

0.01% lotion QD65

Desoximetasone
- 0.25% spray BID66

Betamethasone
dipropionate
- 0.05% spray BID67

Vitamin D analogs
Calcitriol
- 3 mcg/g ointment BID68

• Plaque psoriasis
• Moderate-severe,
affecting ≤20% BSA
• Age ≥18 years
• 1985

• Week 2, IGA = 0/1: 47–55% vs 0–2%
• PASI = NA
• Follow-up = NA

• ≤4 weeks; >2 weeks is
limited to localized
moderate/severe
lesions that insufficiently
improve

•
•
•
•

• Week 2, IGA = 0/1+≥2-GI: 30% vs 9–10%
• PASI = NA
• Follow-up = NA

• Application site: burning (40%), pruritus (3%), dryness
(2%), irritation (1%), pain (1%), pigmentation changes
(1%)
• URTI (8%)
• Nasopharyngitis (5%)
• Pharyngitis streptococcal (1%)
• Application-site discoloration (2%)

oo

• ≤2 weeks

epr

Plaque psoriasis
Moderate-severe
Age ≥18 years
1985

f

Common adverse events (≥1%)

Pr

Halobetasol propionate
- 0.05% lotion BID64

Duration of use

• Plaque psoriasis
• Age ≥18 years
• 1990

• Week 2, IGA = 0/1+≥2-GI: 45% vs 6–7%
• PASI = NA
• Follow-up = NA

• ≤2 weeks

• Application-site atrophy (1%)
• Telangiectasia (1%)
• Headache (1%)

• Plaque psoriasis
• Age ≥18 years
• 1990

• Week 8, IGA = 0/1+≥2-GI: 37–38% vs 8–12%
• PASI = NA
• Follow-up = ≤12 weeks (4 weeks after stopping
therapy) superior to vehicle

• ≤8 weeks

• URTI (2%)
• Application-site dermatitis (1%)
• Hyperglycemia (1%)

• Plaque psoriasis
• Age ≥18 years
• 1977

• Week 4, PGA=0/1: 31–53% vs 5–18%
• PASI = NA
• Follow-up = NA

• ≤4 weeks

• Application site: dryness (2.7%), irritation (2.7%),
pruritus (2%)

•
•
•
•

Plaque psoriasis
Mild-moderate
Age ≥18 years
1975

• Week 2, IGA = 0/1+≥2-GI: 19–22% vs 2–7%
• PASI = NA
• Follow-up = NA

• ≤4 weeks

• Application site: pruritus (6%), burning/stinging
(4.5%), pain (2.3%), atrophy (1.1%)

•
•
•
•

Plaque psoriasis
Mild-moderate
Age ≥18 years
1978

• Week 8, IGA = 0/1+≥2-GI: 21–23% vs 7–14%
• PASI = NA
• Follow-up = NA

• ≤52 weeks

• Hypercalcemia (24%)
• Lab test abnormality (8%)
• Hypercalciuria (3%)
• Skin discomfort (3%)
• Pruritus (1–3%)
• Urine abnormality (4%)

al

0.025% cream BID63

Efficacy outcomes and duration of
response/follow-up; active vs vehicle

rn

-

FDA plaque
psoriasis indication,
initial approval year

Jo
u

Active principle,
vehicle, concentration,
dosing frequency,
Corticosteroids
Clobetasol propionate
- 0.05% spray BID62
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• Psoriasis (4%)
Calcipotriene
- 0.005% foam BID69

-

0.005% cream BID70

Retinoids
Tazarotene
- 0.1% or 0.05% cream
QD71

•
•
•
•
•
•

Plaque psoriasis
Age ≥18 years
1993
Plaque psoriasis
Age ≥18 years
1997

•
•
•
•

Week 8, ISGA = 0/1+≥2-GI: 14–27% vs 7–16%
PASI = NA
Follow-up = NA
Week 8, 50% at least marked improvement; 4%
complete clearing; vehicle NA
• PASI = NA
• Follow-up = NA

• Week 12, overall lesional assessment of none,
minimal, or mild: 39–51% vs 24–26%
• PASI = NA
• Superiority over vehicle as early as Week 1 or 2
for 0.1% or 0.05% cream QD, respectively
• Follow-up = ≤24 weeks (12 weeks after stopping
therapy) superior to vehicle
Therapeutic aryl hydrocarbon receptor modulating agents
Provisional data from one
18, 19, 72
Phase 2b trial
• Plaque psoriasis
• Week 12, PGA = 0/1+≥2-GI: 56% vs 5% (p<0.05)
Tapinarof*
• Week 12, PASI75 = 56% vs 5% (p<0.001)
- 1% cream QD
• Mild-severe
• Age ≥18 years
• Week 12, PASI90 = 40% vs 0% (p=0.001)
• TBD – pending
• PGA and PASI75 responses were observed as
early as Week 2 and were significantly superior to
phase 3 data
vehicle by Week 8
• Follow-up = 16 weeks (4 weeks after stopping
therapy) superior to vehicle for all endpoints

• Application site: pain (3%), erythema (2%)

• ≤8 weeks

• Skin irritation (10–15%)
• Rash, pruritus, dermatitis, and worsening of psoriasis
(1–10%)

• ≤12 weeks

• Pruritus, erythema, and burning (10–23%)

Jo
u

rn

al

Pr

epr

oo

f

• Plaque psoriasis
• Affecting ≤20%
BSA
• Age ≥12 years
• 1997

• ≤8 weeks

• Restrictions not
anticipated†

• Contact dermatitis (11%)
• Folliculitis (5%)
• Application-site dermatitis (5%)
• Miliaria (5%)
• Urticaria (5%)
• Nasopharyngitis (3%)
• Headache (3%)

BID, Twice daily; BSA, body surface area; FDA, Food and Drug Administration; GI, grade improvement; ISGA, Investigator's Static Global Assessment; IGA, Investigator's
Global Assessment; NA, not available; PASI, Psoriasis Area and Severity Index; PASI75, ≤75% improvement in Psoriasis Area and Severity Index; PASI90, ≤90%
improvement in Psoriasis Area and Severity Index; PGA, Physician Global Assessment; QD, once daily; TBD, to be decided; URTI, upper respiratory tract infections.
Table presents registration trial data extracted from FDA labels; comparisons between agents are not recommended in the absence of head-to-head trial data.
*Tapinarof is an investigational drug, data are from a phase 2b randomized controlled trial.

18, 19, 72

Two phase 3 trials, PSOARING 1 (NCT03956355) and PSOARING 2

(NCT03983980) are expected to report in 2020.
†

Restrictions regarding duration of use with tapinarof are not anticipated; more information will be available following completion of a phase 3 long-term extension trial,

PSOARING 3 (NCT04053387).
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Capsule summary
•

Tapinarof is a topical therapeutic aryl hydrocarbon receptor modulating agent
(TAMA) that downregulates IL-17 and promotes skin barrier normalization, with
antioxidant activity
Efficacy and tolerability of tapinarof in psoriasis clinical trials is attributed to its unique
mechanism of action, representing an important potential advance in the
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development of topical medicine
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